Rapamycin passes the torch: a new generation of mTOR inhibitors

Benjamin, Don and Colombi, Marco and Moroni, Christoph and Hall, Michael N.. (2011) Rapamycin passes the torch: a new generation of mTOR inhibitors. Nature Reviews. Drug Discovery, 10 (11). pp. 868-880.

[img] PDF
Restricted to Repository staff only


Official URL: http://edoc.unibas.ch/dok/A5848317

Downloads: Statistics Overview


Mammalian target of rapamycin (mTOR) is an atypical protein kinase that controls growth and metabolism in response to nutrients, growth factors and cellular energy levels, and it is frequently dysregulated in cancer and metabolic disorders. Rapamycin is an allosteric inhibitor of mTOR, and was approved as an immuno-suppressant in 1999. In recent years, interest has focused on its potential as an anticancer drug. However, the performance of rapamycin and its analogues (rapalogues) has been undistinguished despite isolated successes in subsets of cancer, suggesting that the full therapeutic potential of targeting mTOR has yet to be exploited. A new generation of ATP-competitive inhibitors that directly target the mTOR catalytic site display potent and comprehensive mTOR inhibition and are in early clinical trials.
Faculties and Departments:05 Faculty of Science > Departement Biozentrum > Former Organization Units Biozentrum > Growth and Development (Moroni)
03 Faculty of Medicine > Departement Biomedizin > Former Units at DBM > Growth and Development (Moroni)
05 Faculty of Science
05 Faculty of Science > Departement Biozentrum > Growth & Development > Biochemistry (Hall)
UniBasel Contributors:Moroni, Christoph and Hall, Michael N.
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Nature Publishing Group
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
edoc DOI:
Last Modified:29 Aug 2018 16:07
Deposited On:08 Nov 2012 16:15

Repository Staff Only: item control page